For instance, PD-L1 and PD-L2 are the ligands for PD-1, which suppresses the function of activated T cells (35–37), and DLBCL patients within the high-risk group may benefit from therapy using PD-L1 inhibitors. This evidence concerns the gene PDCD1LG2 and diffuse large B-cell lymphoma.